Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly Chief Executive Officer David Ricks told CNBC that approximately one-third of new patients taking the company's GLP-1 pill Foundayo are doing so, according to an interview broadcast on the network. Ricks stated the company is ramping up production to meet demand for the medication. Eli Lilly manufactures Foundayo as an oral formulation in its GLP-1 drug class, which is used for weight management and diabetes treatment. The company did not provide additional details on total patient numbers or production timelines in the statement.

Next story